The findings from trials investigating GLP-1RAs and dual GIP/GLP-1RAs in obesity and OSA represent a significant advancement in managing these conditions, yet there are critical aspects to analyze. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.